Inflazome
AcquiredTargeting inflammation at its source.
Dublin, Ireland · Founded 2016 · $63.0M raised
- Headquarters
- Dublin
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- inflazome.com
- Total Funding
- $63.0M
- Last Round
- $63.0M Series BNov 2018
- Rounds
- 1
- Acquisition Date
- Sep 2020
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Inflazome was a Dublin-based biotech company developing orally available small molecule NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases including Parkinson's, Alzheimer's, arthritis, and cardiovascular conditions. Founded in 2016 by Prof. Matt Cooper and Prof. Luke O'Neill, the company advanced two clinical-stage drugs before being acquired by Roche for €380 million in 2020.
Summary
Inflazome is a Biotech company based in Dublin, Ireland, founded in 2016. It has raised $63.0M in total across 1 round, most recently a $63.0M Series B round in Nov 2018.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
Sep 2020
Sign up to see all 2 events
Funding: Series B. Amounts, valuations, and investors where available.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/inflazome"><img src="https://indexed.vc/api/badge/company/inflazome" alt="Inflazome on Indexed.vc" width="260" height="76" /></a>